1. Background {#sec1-ijerph-15-00903}
=============

Polycystic kidney disease (PKD), a multisystem disorder of ciliary proteins, is occasionally complicated by extra-renal manifestations \[[@B1-ijerph-15-00903]\]. The most prevalent PKD in adulthood is autosomal dominant PKD (ADPKD), which is also the most common detrimental monogenetic disorder \[[@B1-ijerph-15-00903],[@B2-ijerph-15-00903]\]. Although large interfamilial and intrafamilial variations exist in patients with PKD, mutations of the PKD1 (chromosome region 16p13.3, approximately 85% of cases) and PKD2 (4q21, approximately 15% of cases) genes account for most PKD cases \[[@B2-ijerph-15-00903]\].

Previous study suggested that polycystins are associated with the vascular abnormality of blood vessels \[[@B3-ijerph-15-00903]\].

Polycystin 1 (PC1) and polycystin 2 (PC2), the defect proteins in ADPKD, are found in both vascular smooth muscle cells (VSMC) and endothelial cells that are involved in all major vessels including the aorta and intracranial arterials \[[@B4-ijerph-15-00903],[@B5-ijerph-15-00903],[@B6-ijerph-15-00903]\]. The interactions between PC1/PC2 and VSMCs are complex. Previous data indicated that the dysregulation of Ca^2+^ homeostasis, which resulted from the mutation of PC1/PC2, may lead to an increase in VSMC proliferation and apoptosis resembling the P*kd*-mutant phenotype \[[@B7-ijerph-15-00903]\].

Moreover, several lines of studies suggested that the mTOR signaling pathway is involved with patho-physiological changes of VSMCs including proliferation, differentiation, and migration with increased extracellular matrix protein synthesis \[[@B8-ijerph-15-00903]\].

VSMCs after injury are frequently prone to abnormal proliferation and matrix synthesis which eventually contributes to intimal hyperplasia and lumen narrowing in vessels \[[@B9-ijerph-15-00903]\].

The mTOR pathway inhibitor is shown to be effective in the attenuation of intimal hyperplasia in an animal model and clinical trials \[[@B10-ijerph-15-00903],[@B11-ijerph-15-00903]\].

There is overwhelming evidence for the hyperactivity of mTOR signaling in PKD \[[@B12-ijerph-15-00903],[@B13-ijerph-15-00903]\]. Edelstein et al. firstly found that mTOR could involve the progression of cyst changes in the Han: SPRD rat model of PKD \[[@B14-ijerph-15-00903]\]. In addition, Shillingford et al. further demonstrated a substantial role of mTOR contributing to the pathogenesis of human PKD and suggested that patients with PKD are likely to be associated with an aberrant activity of mTOR \[[@B15-ijerph-15-00903]\].

Accordingly, it is reasonable to suppose that PKD is associated with a higher risk of vascular complications because of the hyperactivity of mTOR resulting from a PC1/2 deficiency.

In patients with PKD, the underlying defect in the connective tissue matrix has been associated with various extrarenal manifestations including intracranial aneurysms, hepatic cysts, diverticulosis, spontaneous coronary artery dissection (SCAD), atrial fibrillation \[[@B16-ijerph-15-00903]\], and other cardiovascular abnormalities \[[@B17-ijerph-15-00903]\].

However, data regarding the relationship between PKD and the risk of cardiovascular events such as coronary artery disease and cerebral vascular disease remain limited, particularly for acute coronary syndrome (ACS) characterized by unstable angina with a non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction, which is a life-threatening condition \[[@B18-ijerph-15-00903],[@B19-ijerph-15-00903]\].

In the current study, we used the large claims database of the Taiwan National Health Insurance (NHI) program to conduct a nationwide cohort study to investigate the risk of cardiovascular events, including ACS and stroke, in patients with PKD.

2. Materials and Methods {#sec2-ijerph-15-00903}
========================

2.1. Data Source {#sec2dot1-ijerph-15-00903}
----------------

The NHI program covers more than 99% of the population of Taiwan (<http://www.nhi.gov.tw/english/index.aspx>). The Bureau of National Health Insurance authorized the Taiwan National Health Research Institutes to manage the electronic medical records of patients enrolled in this program and establish the National Health Insurance Research Database (NHIRD) for research purposes. Information available in the database includes the demographic status of insurants; medical diagnoses, treatment procedures, and drug prescriptions for inpatient and outpatient services; and healthcare facilities providing care services to patients. For this study, we used a subset of the NHIRD containing health care data including files of inpatients claims, and the Registry of Beneficiaries. To ensure the privacy of personal information, unique encrypted identification numbers are used for all patients. All claimed data sets can be linked using these anonymous identification numbers. All diagnoses were defined using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

2.2. Data Availability Statement {#sec2dot2-ijerph-15-00903}
--------------------------------

The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The Ministry of Health and Welfare must approve our application to access this data. Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of MOHW (Email: stcarolwu\@mohw.gov.tw) for further assistance. Taiwan Ministry of Health and Welfare Address: No. 488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All relevant data are within the paper.

2.3. Ethics Statement {#sec2dot3-ijerph-15-00903}
---------------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR2). The IRB also specifically waived the consent requirement.

2.4. Study Patients {#sec2dot4-ijerph-15-00903}
-------------------

[Figure 1](#ijerph-15-00903-f001){ref-type="fig"} shows the selection process of the participants in the 2 study cohorts. From the inpatient database, we chronologically identified 5721 patients aged ≥20 years who were newly diagnosed with PKD (ICD-9-CM codes 753.12 and 753.13) between 2000 and 2011. The diagnosis date was designated as the "start date" of the follow-up period (in years). For each PKD patient, we randomly selected 4 controls frequency-matched by sex, age, start date, and comorbidities of hypertension (ICD-9-CM codes 401--405), diabetes (ICD-9-CM code 250), chronic obstructive pulmonary disease (COPD; ICD-9-CM codes 491, 492, and 496), chronic kidney disease (CKD; ICD-9-CM code 585), hyperlipidemia (ICD-9-CM code 272), and end-stage renal disease (ESRD; ICD-9-CM code 585 with catastrophic certification). We gave the controls (non-PKD cohort) the same start year as cases (PKD cohort) and then randomly assigned months and days to the controls as the start date of the controls. The study populations in both cohorts were followed from the start dates until the development of ACS or other events of interest, until they were censored for loss to follow-up or withdrawal from the NHI program, or until the end of 2011. The primary goal of this study was to compare the risk of 3 outcomes and mortality between patients with and without PKD: (1) ACS (ICD-9-CM codes 410, 411.1, and 411.8) including unstable angina (ICD-9-CM code 411.1), NSTEMI (ICD-9-CM codes 410.70--410.72), and STEMI (ICD-9-CM codes 410.0--410.9, except for codes 410.70--710.72); (2) stroke (ICD-9-CM codes 430--438) including hemorrhagic stroke (ICD-9-CM codes 430--432) and ischemic stroke (ICD-9-CM codes 433--438); and (3) heart failure (ICD-9-CM code 428) as well as patient death. Patients identified with these disorders were excluded at the baseline.

2.5. Statistical Analysis {#sec2dot5-ijerph-15-00903}
-------------------------

Distributions of sex, age (20--49, 50--64, and ≥65 years), and comorbidities (yes and no) were compared between the cohorts with and without PKD. We used the Chi-squared test to examine categorical variables and the Wilcoxon rank-sum test to examine the skewed age distributions between the groups. For events significantly associated with PKD, we used the Kaplan--Meier method to calculate and plot the cumulative incidences of such events and examined the differences between the cohorts by using the log-rank test. We also calculated the overall incidence rates of each study event in both cohorts. Because mortality was a critical factor affecting the estimation of ACS, stroke, and heart failure risk, we considered the event of death as a competing event to estimate subhazard ratios (SHRs) and 95% confidence intervals (CIs) by using the standard univariable and multivariable Cox proportional hazards regression models \[[@B20-ijerph-15-00903]\]. Cox regression models were used to calculate the crude hazard ratios (HRs) and 95% CIs of PKD-related mortality in the PKD and non-PKD cohorts. We also used events with a significant crude SHR (cSHR) or crude HR to calculate the relative adjusted SHR (aSHR) or adjusted HR (aHR) of the events associated with PKD through multivariable Cox regression analysis after controlling the baseline characteristics. The joint effect between PKD and the comorbidities was also measured for outcome events that were significantly associated with PKD. SAS 9.3 statistical software (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses. The 2-sided significance level was set at 0.05.

3. Results {#sec3-ijerph-15-00903}
==========

[Table 1](#ijerph-15-00903-t001){ref-type="table"} presents the baseline data of the PKD and comparison cohorts; the baseline characteristics were similar in both cohorts. As shown in [Figure 2](#ijerph-15-00903-f002){ref-type="fig"}, the cumulative incidence rates of ACS, stroke, congestive heart failure (CHF), and mortality were all greater in the PKD cohort than in the non-PKD cohort.

[Table 2](#ijerph-15-00903-t002){ref-type="table"} shows the overall incidence rates of the 3 events between the PKD and non-PKD cohorts as well as the cSHRs of the events in these cohorts. The PKD patients were at a higher risk of all events than the comparisons. Overall, comparing the PKD and non-PKD cohorts revealed that the PKD cohort had a higher incidence of ACS (8.59 vs. 6.17 per 1000 person-years), unstable angina (1.98 vs. 1.26 per 1000 person-years), stroke (21.5 vs. 16.1 per 1000 person-years), hemorrhagic stroke (6.16 vs. 2.97 per 1000 person-years), ischemic stroke (15.3 vs. 13.2 per 1000 person-years), and CHF (16.3 vs. 11.1 per 1000 person-years), corresponding to cSHR values of 1.40 (95% CI = 1.22--1.61), 1.41 (95% CI = 1.05--1.89), 1.40 (95% CI = 1.28--1.53), 2.12 (95% CI = 1.78--2.53), 1.20 (95% CI = 1.08--1.33), and 1.49 (95% CI = 1.34--1.65), respectively. The sex-specific PKD-to-non-PKD cohort relative risk of ACS was significant for men (cSHR = 1.47, 95% CI = 1.24--1.74). Furthermore, the age-specific PKD-to-non-PKD relative risk of ACS was high for all age groups. Notably, in the group aged 20--49 year-old, a 1.61-fold increased risk of ACS (95% CI = 1.18, 2.21), 1.65-fold in stroke (95% CI = 1.32, 2.07), and 1.82-fold in CHF (95% CI = 1.37, 2.42) was noted.

PKD patients with comorbidities were associated with significantly higher risks of ACS than the non-PKD patients. The PKD cohort was 1.40-fold more likely to develop stroke (95% CI = 1.28--1.53), 2.12-fold more likely to develop hemorrhagic stroke (95% CI = 1.78--2.53), and 1.20-fold more likely to develop ischemic stroke (95% CI = 1.08--1.33) compared with the non-PKD cohort. We compared the risks of stroke and CHF between the PKD and non-PKD cohorts in terms of several variables including sex, age, and the presence or absence of comorbidities. In all stratifications, the risks of stroke and CHF in the PKD cohort were higher than those in the non-PKD cohort, except for patients without comorbidities.

[Table 3](#ijerph-15-00903-t003){ref-type="table"} shows a significantly high risk of mortality in patients with PKD compared to that in patients without PKD which reached a 1.64-fold increase (95% CI = 1.53--1.75). In stratification with sex and age shows that the sex-specific PKD-to-non-PKD cohort relative risk of mortality was significant for men (cHR = 1.60, 95% CI = 1.47--1.73) as well as that in women (cHR = 1.75, 95% CI = 1.57--1.97). Furthermore, the age-specific PKD-to-non-PKD relative risk of mortality was high for all age groups. Notably, in the group aged 20--49 year-old, a 1.84-fold increased risk of mortality (95% CI = 1.55, 2.18).

[Table 4](#ijerph-15-00903-t004){ref-type="table"} presents the calculated cSHRs and aSHRs of the 3 PKD-related events and cHRs and aHRs of the mortality after adjustment for sex, age, and baseline comorbidities. Men were at higher risks of ACS, stroke and mortality than women. The hazard of heart failure was higher for patients aged 50--64 years than for those aged 20--49 years. Hypertension, diabetes, CKD, and ESRD were associated with increased risks of ACS, stroke, CHF, and mortality.

4. Discussion {#sec4-ijerph-15-00903}
=============

In this large population-based cohort study with a long observation period of 27,053 person-years, we noted that PKD patients had a significantly higher risk of ACS as well as CHF when compared with non-PKD patients after adjustment for age, sex, and the associated cardiovascular risk factors included hypertension, diabetes, hyperlipidemia, COPD, and CKD. We also found greater risks of stroke and mortality for the PKD cohort than for the non-PKD cohort. Interestingly, our findings disclosed a significantly increased risk of cardiovascular events including ACS, stroke, and CHF in young patients with PKD, which has never been reported previously for such a relatively young age group.

Cardiovascular complications have surpassed infections among the most common causes of morbidity and mortality in patients with PKD \[[@B18-ijerph-15-00903],[@B19-ijerph-15-00903]\]. Some cardiovascular risk factors have been suggested to be closely associated with PKD. Hypertension and left ventricular hypertrophy are commonly observed in patients with PKD \[[@B19-ijerph-15-00903],[@B21-ijerph-15-00903]\]. Early vascular changes have been reported in young patients with normal blood pressure, and patients with PKD are considered to have a higher prevalence of coronary aneurysm (CA) and cardiac valvular abnormalities than the general population does \[[@B19-ijerph-15-00903]\]. Nevertheless, diagnosing SCAD is extremely challenging. Even in patients with a strong clinical suspicion, SCAD is difficult to diagnose accurately by using coronary angiography \[[@B22-ijerph-15-00903]\]. Previous studies on SCAD associated with PKD are limited to a few case reports and a study with a small sample size \[[@B23-ijerph-15-00903],[@B24-ijerph-15-00903],[@B25-ijerph-15-00903]\].

In the present study, after adjusting for associated risk factors including hypertension, diabetes, hyperlipidemia, and chronic kidney disease, multivariate analysis revealed a relatively high hazard of ACS as well as stroke in patients with PKD compared with non-PKD patients. Notably, the age-specific risk of ACS was significantly higher for those who were younger, aged 20--49 years (HR = 1.61, 95% CI = 1.18--2.21), and additionally a 1.82-fold increased risk of CHF was observed in young people with PKD. In addition, the trend is consistent in that a 1.65-fold increased risk of stroke was observed.

More recently, a study on PKD patients indicated that a high prevalence of young-onset hypertension was observed in children with PKD and that may partly support the findings in the present study.

In terms of stratification without co-morbidity, our results showed that the risk of CVD was comparable between patients with and without PKD. The findings may suggest that the associated cardiovascular co-morbidity may contribute more greatly in patients once they have PKD.

Taken together, our findings indicate a higher risk of cardiovascular events in younger patients with PKD that was never previously known.

Previous studies have shown that polycystins are constitutional in normal adult smooth muscle cells \[[@B5-ijerph-15-00903],[@B6-ijerph-15-00903]\]. Polycystins may play an essential role in maintaining the vascular integrity of the myoelastic structure of the arterial wall \[[@B26-ijerph-15-00903]\]. An animal study showed that the null mutation of the PKD1 or PKD2 gene could diffuse vascular rupture and hemorrhage in the vessel tissue, suggesting that polycystins have a role in maintaining vascular integrity \[[@B5-ijerph-15-00903],[@B27-ijerph-15-00903]\]. Hence, polycystin deficiency is suggested to be directly attributed to the various phenotypes of vascular abnormality in patients with ADPKD, which are independent of the effect of hypertension \[[@B6-ijerph-15-00903]\].

Moreover, accumulating evidence indicates that PKD is likely associated with aberrant mTOR activity. Previous study demonstrated that the cytoplasmic tail of PC1 could inhibit mTOR and the loss function of PC1 in ADPKD would eventually lead to a remarkable hyperactivity of mTOR \[[@B13-ijerph-15-00903],[@B15-ijerph-15-00903]\].

We previously demonstrated that PKD is significantly associated with the risk of cancer, within which mTOR may play an important role \[[@B28-ijerph-15-00903]\]. Whether mTOR has a similar role within it needs further elucidation.

Our study results may provide clinical evidence relevant to previous biological evidence.

Previous study has suggested that a rennin-angiotensin blockade was likely associated with a favorable outcome in PKD patients. Therefore, in terms of cardiovascular complications, it should be firstly considered in PKD patients. Certain limitations of the present study should be considered. First, some data on tobacco smoking and kidney function as glomerular filtration rate are relevant to the risk of ACS but are not provided in the NHIRD. Therefore, we included the confounder of COPD, chronic kidney disease, and end stage renal disease (ESRD) in the multivariable analysis to correct any possible bias. Second, we could not obtain details regarding CA and SCAD. The clinical diagnosis of SCAD is challenging and relies completely on visualizing a radiolucent intimal "flap" in coronary angiography \[[@B22-ijerph-15-00903],[@B29-ijerph-15-00903]\]. In practice, delineating the coronary wall through ordinary cardiac angiography is difficult, limiting its diagnostic accuracy \[[@B22-ijerph-15-00903],[@B29-ijerph-15-00903],[@B30-ijerph-15-00903]\]. Nevertheless, the diagnoses of ACS and AMI in the study were not biased by this condition. Third, we did not consider the effects of medications including antihypertensive, antiplatelet, and antidiabetic drugs. This may have led to an underestimation of the risk of ACS in the study. Finally, we could not analyze biological data obtained through genetic analysis including the mutations of the PKD1 and PKD2 genes. We could not examine the individual risks of vascular phenotypes in the study cohort, although this is not necessary for the contemporary diagnosis of PKD or ADPKD.

5. Conclusions {#sec5-ijerph-15-00903}
==============

Our study reports for the first time that patients with PKD are at increased risk of ACS as well as other cardiovascular events including stroke, CHF, and mortality.

Most important of all, our findings show that young adult PKD is significantly associated with a higher risk of cardiovascular disease when compared with non-PKD patients. The relatively high risk of cardiovascular events such as stroke and heart failure, as well as mortality, should not be ignored in young patients with PKD, and early recognition of the cardiovascular risk in such patients is required.
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###### 

Characteristics of patients between patients with and without polycystic kidney disease (PKD).

  Age, Year                Polycystic Kidney Disease   *p*-Value                              
  ------------------------ --------------------------- -------------- -------- -------------- ------
  20--49                   2080                        36.4           8308     36.4           
  50--64                   1676                        29.3           6695     29.3           
  ≥65                      1965                        34.4           7854     34.4           
  Median (IQR) ^\#^        56.0                        (45.1--70.3)   56.1     (45.1--70.5)   0.76
  Gender                                                                                      0.98
  Female                   2250                        44.6           10,192   44.6           
  Male                     3171                        55.4           12,665   55.4           
  Comorbidity                                                                                 
  Hypertension             2504                        43.8           10,006   43.8           0.99
  Diabetes                 610                         10.7           2432     10.6           0.96
  Hyperlipidemia           236                         4.13           933      4.08           0.88
  COPD                     327                         5.72           1293     5.66           0.86
  Chronic kidney disease   1234                        21.6           4915     21.5           0.91
  ESRD                     564                         9.86           2239     9.80           0.89

Chi-square test; ^\#^ Wilcoxon signed rank test. IQR: interquartile range. COPD: chronic obstructive pulmonary disease. ESRD: end-stage renal disease.

ijerph-15-00903-t002_Table 2

###### 

Incidence and hazard ratio of outcome between patients with and without polycystic kidney disease.

  Variable                   Polycystic Kidney Disease   Crude SHR ^†^ (95% CI)                                                    
  -------------------------- --------------------------- ------------------------ -------- ------ -------- ------ --------- ------ ------------------
  ACS                                                                                                                              
  All                        5721                        252                      29,323   8.59   22,857   790    128,080   6.17   1.40(1.22, 1.61)
  Unstable angina                                        58                                1.98            161              1.26   1.41(1.05, 1.89)
  NSTMI                                                  21                                0.72            77               0.60   0.94(0.59, 1.50)
  STMI                                                   69                                2.35            238              1.86   1.14(0.88, 1.49)
  Gender                                                                                                                           
  Female                     2550                        72                       14,002   5.14   10,192   245    59,827    4.10   1.26(0.98, 1.64)
  Male                       3171                        180                      15,322   11.8   12,665   545    68,253    7.99   1.47(1.24, 1.74)
  Age, year                                                                                                                        
  20--49                     2080                        54                       12,584   4.29   8308     131    51,120    2.56   1.61(1.18, 2.21)
  50--64                     1676                        84                       8865     9.48   6695     216    38,289    5.64   1.67(1.30, 2.15)
  ≥65                        1965                        114                      7874     14.5   7854     443    38,671    11.5   1.28(1.04, 1.57)
  Comorbidity ^§^                                                                                                                  
  No                         37                          2                        268      7.47   148      7      1101      6.36   1.11(0.23, 5.24)
  Yes                        5684                        250                      29,055   8.60   22,709   783    126,978   6.17   1.40(1.22, 1.61)
  Stroke                                                                                                                           
  All                        5721                        609                      28,395   21.5   22,857   2002   124,216   16.1   1.40(1.28, 1.53)
  Hemorrhagic stroke                                     175                      28,396   6.16            369    124,216   2.97   2.12(1.78, 2.53)
  Ischemic stroke                                        434                      28,396   15.3            1633   124,216   13.2   1.20(1.08, 1.33)
  Gender                                                                                                                           
  Female                     2550                        237                      13,533   17.5   10,192   677    58,390    11.6   1.62(1.40, 1.88)
  Male                       3171                        372                      14,863   25.0   12,665   1325   65,826    20.1   1.29(1.15, 1.45)
  Age, year                                                                                                                        
  20--49                     2080                        108                      12,419   8.70   8308     265    50,742    5.22   1.65(1.32, 2.07)
  50--64                     1676                        176                      8628     20.4   6695     537    37,243    14.4   1.41(1.19, 1.67)
  ≥65                        1965                        325                      7349     44.2   7854     1200   36,231    33.1   1.35(1.19, 1.52)
  Comorbidity ^§^                                                                                                                  
  No                         37                          4                        254      15.7   148      17     1060      16.0   0.98(0.33, 2.89)
  Yes                        5684                        605                      28,142   21.5   22,709   1985   123,156   16.1   1.41(1.28, 1.54)
  Congestive heart failure                                                                                                         
  All                        5721                        471                      28,987   16.3   22,857   1410   126,905   11.1   1.49(1.34, 1.65)
  Gender                                                                                                                           
  Female                     2550                        171                      13,806   12.4   10,192   531    59,153    8.98   1.43(1.21, 1.69)
  Male                       3171                        300                      15,181   19.8   12,665   879    67,751    13.0   1.52(1.34, 1.73)
  Age, year                                                                                                                        
  20--49                     2080                        69                       12,585   5.48   8308     150    51,123    2.93   1.82(1.37, 2.42)
  50--64                     1676                        116                      8866     13.1   6695     336    37,950    8.85   1.46(1.18, 1.80)
  ≥65                        1965                        286                      7537     38.0   7854     924    37,832    24.4   1.57(1.38, 1.80)
  Comorbidity ^§^                                                                                                                  
  No                         37                          0                        276      0.00   148      7      1107      6.32   \-
  Yes                        5684                        471                      28,711   16.4   22,709   1403   125,798   11.2   1.50(1.35, 1.66)

ACS, acute coronary syndrome. PY, person-years; Rate ^\#^, incidence rate per 1000 person-years. Crude SHR ^†^, relative hazard ratio. Comorbidity ^§^: Patients with any one of the comorbidities (including hypertension, diabetes, hyperlipidemia, COPD, chronic kidney disease and ESRD) were classified as the comorbidity group. NSTMI: non-ST elevation myocardial infarction. STMI: ST elevation myocardial infarction.

ijerph-15-00903-t003_Table 3

###### 

Incidence and hazard ratio of mortality between patients with and without polycystic kidney disease.

  Variable          Polycystic Kidney Disease   Crude HR ^†^ (95% CI)                                                    
  ----------------- --------------------------- ----------------------- -------- ------ -------- ------ --------- ------ ------------------
  All               5721                        1217                    30,045   40.5   22,857   3218   130,270   24.7   1.64(1.53, 1.75)
  Gender                                                                                                                 
  Female            2550                        416                     14,224   29.3   10,192   1012   60,548    16.7   1.75(1.57, 1.97)
  Male              3171                        801                     15,822   50.6   12,665   2206   69,721    31.6   1.60(1.47, 1.73)
  Age, year                                                                                                              
  20--49            2080                        191                     12,778   15.0   8308     421    51,648    8.15   1.84(1.55, 2.18)
  50--64            1676                        347                     9154     37.9   6695     875    38,931    22.5   1.69(1.50, 1.92)
  ≥65               1965                        679                     8113     83.7   7854     1922   39,690    48.4   1.73(1.59, 1.89)
  Comorbidity ^§^                                                                                                        
  No                37                          7                       276      25.3   148      13     1122      11.6   2.14(0.86, 5.38)
  Yes               5684                        1210                    29,769   40.7   22,709   3205   129,148   24.8   1.64(1.53, 1.75)

PY, person-years; Rate ^\#^, incidence rate per 1000 person-years. Crude HR ^†^, relative hazard ratio. Comorbidity ^§^: Patients with any one of the comorbidities (including hypertension, diabetes, hyperlipidemia, COPD, chronic kidney disease and ESRD) were classified as the comorbidity group.
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Hazard ratios of outcome in association with gender, age and comorbidities in univariable and multivariable competing risk models.

  Variable                              ACS                Stroke              Congestive Heart Failure   Mortality                                                                   
  ------------------------------------- ------------------ ------------------- -------------------------- ------------------ ------------------ ------------------ ------------------ ------------------
  PKD                                   1.40(1.22, 1.61)   1.40(1.22, 1.62)    1.40(1.28, 1.53)           1.39(1.27, 1.52)   1.49(1.34, 1.65)   1.51(1.36, 1.68)   1.64(1.53, 1.75)   1.71(1.60, 1.83)
  Gender (Men vs. women)                1.58(1.39, 1.79)   1.55(1.36, 1.77)    1.30(1.20, 1.40)           1.27(1.17, 1.38)   1.07(0.98,1.17)    1.03(0.94, 1.13)   1.84(1.73, 1.96)   1.42(1.33, 1.51)
  Age, years                                                                                                                                                                          
  20--49                                1(Reference)       1(Reference)        1(Reference)               1(Reference)       1(Reference)       1(Reference)       1(Reference)       1(Reference)
  50--64                                1.37(1.03, 1.82)   1.19(0.89, 1.59)    1.28(1.04, 1.57)           1.04(0.84, 1.28)   1.79(1.40, 2.29)   1.45(1.13, 1.84)   2.69(2.44, 2.96)   2.32(2.11, 2.56)
  ≥65                                   1.23(0.99, 1.54)   1.08(0.87, 1.35)    1.25(1.07, 1.46)           1.12(0.96, 1.30)   1.31(1.08, 1.58)   1.10(0.91, 1.33)   5.78(5.29, 6.32)   5.16(4.72, 5.65)
  Baseline comorbidities (yes vs. no)                                                                                                                                                 
  Hypertension                          1.96(1.74, 2.21)   1.76(1.55, 1.99)    1.61(1.49, 1.74)           1.51(1.39, 1.63)   1.69(1.54, 1.85)   1.53(1.39, 1.68)   1.69(1.59, 1.79)   1.21(1.14, 1.28)
  Diabetes                              2.21(1.90, 2.57)   1.87(1.60, 2.18)    1.79(1.62, 1.98)           1.65(1.48, 1.83)   2.20(1.97, 2.45)   2.00(1.78, 2.24)   2.07(1.92, 2.24)   1.67(1.54, 1.81)
  Hyperlipidemia                        2.40(1.95, 2.95)   1.87((1.51, 2.32)   1.41(1.20, 1.67)           1.12(0.95, 1.33)   1.69(1.41, 2.02)   1.33(1.10, 1.59)   1.07(0.93, 1.24)   0.88(0.76, 1.02)
  COPD                                  1.37(1.10, 1.70)   1.16(0.93, 1.44)    1.42(1.25, 1.61)           1.30(1.14, 1.48)   1.72(1.50, 1.98)   1.52(1.32, 1.76)   2.76(2.51, 3.03)   1.60(1.45, 1.76)
  CKD                                   2.20(1.94, 2.49)   1.90(1.65, 2.20)    1.73(1.60, 1.89)           1.64(1.49, 1.81)   2.52(2.30, 2.76)   2.37(2.14, 2.63)   3.36(3.17, 3.56)   2.76(2.58, 2.95)
  ESRD                                  2.12(1.78, 2.52)   1.32(1.07, 1.61)    1.52(1.33, 1.73)           1.03(0.89, 1.20)   2.19(1.92, 2.50)   1.29(1.11, 1.50)   2.80(2.60, 3.02)   1.60(1.47, 1.74)

Crude SHR ^†^, relative subhazard ratio; Crude HR ^†^, relative hazard ratio; Adjusted SHR ^‡^ and Adjusted HR ^‡^: multivariable analysis including gender, age, and comorbidities of hypertension, diabetes, hyperlipidemia, COPD, chronic kidney disease (CKD), and ESRD.

[^1]: Authors equally contributed to this work.
